Author Correction: Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis

Amal M El-Naggar^{1

2

3}, Syam Prakash Somasekharan^#⁴, Yemin Wang^#², Hongwei Cheng^#⁴, Gian Luca Negri^#⁵, Melvin Pan², Xue Qi Wang², Alberto Delaidelli^{1

2}, Bo Rafn², Jordan Cran², Fan Zhang⁴, Haifeng Zhang^{1

2}, Shane Colborne⁵, Martin Gleave⁴, Anna Mandinova⁶, Nancy Kedersha⁷, Christopher S Hughes², Didier Surdez⁸, Olivier Delattre⁸, Yuzhuo Wang⁴, David G Huntsman^{1

2}, Gregg B Morin⁵, Poul H Sorensen^{9

10}

Affiliations

¹ Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 2B5, Canada.
² Department of Molecular Oncology, BC Cancer, part of the Provincial Health Services Authority, Vancouver, BC, V5Z1L3, Canada.
³ Department of Pathology, Faculty of Medicine, Menoufia University, Shibin Al Kawm, Egypt.
⁴ Vancouver Prostate Centre, Vancouver, BC, V5Z 1M9, Canada.
⁵ Michael Smith Genome Sciences Centre, Vancouver, BC, V5Z4S6, Canada.
⁶ Brigham and Women's Hospital, Harvard University, Boston, MA, 02115, USA.
⁷ Massachusetts General Hospital, Harvard University, Boston, MA, 02114, USA.
⁸ Centre de recherche de l'Institut Curie, 75005, Paris, France.
⁹ Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 2B5, Canada. psor@mail.ubc.ca.
¹⁰ Department of Molecular Oncology, BC Cancer, part of the Provincial Health Services Authority, Vancouver, BC, V5Z1L3, Canada. psor@mail.ubc.ca.

^# Contributed equally.

Published Erratum

Amal M El-Naggar et al. EMBO Rep. 2025 Jun.

. 2025 Jun;26(12):3226-3227.

doi: 10.1038/s44319-025-00478-6.

¹ Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 2B5, Canada.
² Department of Molecular Oncology, BC Cancer, part of the Provincial Health Services Authority, Vancouver, BC, V5Z1L3, Canada.
³ Department of Pathology, Faculty of Medicine, Menoufia University, Shibin Al Kawm, Egypt.
⁴ Vancouver Prostate Centre, Vancouver, BC, V5Z 1M9, Canada.
⁵ Michael Smith Genome Sciences Centre, Vancouver, BC, V5Z4S6, Canada.
⁶ Brigham and Women's Hospital, Harvard University, Boston, MA, 02115, USA.
⁷ Massachusetts General Hospital, Harvard University, Boston, MA, 02114, USA.
⁸ Centre de recherche de l'Institut Curie, 75005, Paris, France.
⁹ Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 2B5, Canada. psor@mail.ubc.ca.
¹⁰ Department of Molecular Oncology, BC Cancer, part of the Provincial Health Services Authority, Vancouver, BC, V5Z1L3, Canada. psor@mail.ubc.ca.

^# Contributed equally.

Abstract

Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis.
El-Naggar AM, Somasekharan SP, Wang Y, Cheng H, Negri GL, Pan M, Wang XQ, Delaidelli A, Rafn B, Cran J, Zhang F, Zhang H, Colborne S, Gleave M, Mandinova A, Kedersha N, Hughes CS, Surdez D, Delattre O, Wang Y, Huntsman DG, Morin GB, Sorensen PH. El-Naggar AM, et al. EMBO Rep. 2019 Dec 5;20(12):e48375. doi: 10.15252/embr.201948375. Epub 2019 Oct 31. EMBO Rep. 2019. PMID: 31668005 Free PMC article.